#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14248	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2189	642.0	0	.	n	.	0	A800G	SNP	800	800	A	1040	1040	G	802	G,A	749,23	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14248	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2189	642.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1690	1690	T	811	T,C	777,4	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14248	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2189	642.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1424	1424	C	827	C,T	785,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27202	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3894	691.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1868	1868	A	962	A,G	901,25	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27202	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3894	691.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2502	2502	C	789	C	754	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27202	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3894	691.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2576	2576	A	771	A	749	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27202	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3894	691.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3128	3128	C	872	C	840	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1736	folP	855	855	100.0	folP.l15.c4.ctg.1	1509	113.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1006	1008	AGC	189;187;190	A;G;C	180;180;176	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4700	gyrA	2751	2751	99.96	gyrA.l6.c30.ctg.1	3392	137.0	1	SNP	p	S91F	1	.	.	271	273	TTC	512	514	TTC	162;159;160	T;T;C	157;155;155	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4700	gyrA	2751	2751	99.96	gyrA.l6.c30.ctg.1	3392	137.0	1	SNP	p	G95N	0	.	.	283	285	GGC	524	526	GGC	159;156;157	G,A;G,A;C	148,4;147,4;150	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4700	gyrA	2751	2751	99.96	gyrA.l6.c30.ctg.1	3392	137.0	1	SNP	p	D95G	1	.	.	283	285	GGC	524	526	GGC	159;156;157	G,A;G,A;C	148,4;147,4;150	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1550	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1390	110.4	1	SNP	p	G45D	0	.	.	133	135	GGC	495	497	GGC	216;215;214	G;G,A;C	211;208,1;205	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	808	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1154	69.2	0	.	n	.	0	A197.	DEL	197	197	A	729	729	A	177	A	170	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4360	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2954	146.2	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1519	1521	GTC	175;175;177	G;T;C	171;162;171	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4360	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2954	146.2	1	SNP	p	D86N	0	.	.	256	258	GAC	625	627	GAC	156;157;163	G;A;C	155;150;161	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4360	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2954	146.2	1	SNP	p	R87W	0	.	.	259	261	CGT	628	630	CGT	164;166;166	C,A;G,T;T	162,2;161,2;160	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4360	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2954	146.2	1	SNP	p	S87R	1	.	.	259	261	CGT	628	630	CGT	164;166;166	C,A;G,T;T	162,2;161,2;160	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4360	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2954	146.2	1	SNP	p	R87I	0	.	.	259	261	CGT	628	630	CGT	164;166;166	C,A;G,T;T	162,2;161,2;160	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4360	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2954	146.2	1	SNP	p	S88P	0	.	.	262	264	TCC	631	633	TCC	165;165;165	T;C;C	158;162;160	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3938	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2617	148.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1328	1330	TGC	193;195;193	T,C;G;C	179,7;186;187	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3938	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2617	148.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1538	1540	GGC	242;239;236	G;G;C,A	234;230;229,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1228	1230	GCA	191;196;199	G;C;A	185;188;189	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1231	1233	ATC	200;200;199	A,T;T;C	191,1;191;191	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1243	1245	GTG	198;196;197	G;T;G	190;188;192	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1243	1245	GTG	198;196;197	G;T;G	190;188;192	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1747	1749	ACC	162;161;161	A;C;C,G	154;155;155,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1801	1803	GCG	163;160;160	G,A;C,G;G	151,3;138,4;153	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1801	1803	GCG	163;160;160	G,A;C,G;G	151,3;138,4;153	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1924	1926	GGC	157;153;150	G,A;G;C	146,4;146;144	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1933	1935	GGC	150;147;146	G;G;C	143;141;139	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3798	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2467	151.9	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1951	1953	TCG	139;142;145	T,G,C;C;G	96,19,1;124;128	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5970	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3203	184.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1834	1836	CCG	204;203;202	C;C,T;G	190;195,1;191	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2270	porA	1146	1146	99.56	porA.l6.c17.ctg.1	1791	125.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	576	576	C	161	C	149	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	V258L	NONSYN	772	774	GTA	113	115	TTA	45;47;47	T;T;A	43;45;45	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	158	160	CAT	45;43;43	C,G;A;T	42,1;41;42	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	161	163	AGT	43;42;42	A,G;G,A;T	41,1;40,1;42	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	170	172	TAC	44;44;45	T,C;A;C	42,1;44;45	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	R307A	NONSYN	919	921	AGA	260	262	GCA	19;19;19	G;C,A;A	19;18,1;19	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	272	274	GCA	18;17;17	G;C;A	18;17;17	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	275	277	GAC	17;17;17	G;A;C	17;17;17	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	281	283	ATC	17;17;17	A;T;C	16;17;17	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	287	289	TCG	17;16;15	T;C;G	16;15;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	293	295	GCC	15;15;15	G;C;C	14;14;13	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	296	298	AGC	15;15;15	A;G,A;C	15;14,1;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	299	301	GCC	15;15;15	G;C;C	15;14;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	332	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	454	23.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	305	307	GTT	15;15;15	G;T;T	15;15;13	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2856	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1439	194.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	359	361	GAA	218;218;218	G;A;A	209;205;205	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2856	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1439	194.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	647	649	GAT	246;246;246	G,A;A;T	226,12;238;234	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2856	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1439	194.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	770	772	TCA	220;222;221	T;C;A	210;217;214	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2856	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1439	194.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	899	901	GTC	234;232;237	G,A;T;C,G	219,1;224;226,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2856	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1439	194.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1229	1231	GCA	208;211;212	G;C,A;A	199;195,8;203	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2856	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1439	194.7	1	SNP	p	G120K	1	.	.	358	360	AAG	605	607	AAG	245;246;248	A;A;G	235;236;238	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2856	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1439	194.7	1	SNP	p	D121N	0	.	.	361	363	GAC	608	610	GAC	249;247;248	G;A;C	240;238;242	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2856	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1439	194.7	1	SNP	p	A121D	1	.	.	361	363	GAC	608	610	GAC	249;247;248	G;A;C	240;238;242	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10424	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4938	209.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2015	2017	AAT	224;229;234	A,C;A;T	215,2;221;225	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1194	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1070	110.1	1	SNP	p	V57M	1	.	.	169	171	ATG	600	602	ATG	263;263;259	A;T;G	256;254;251	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
